BHUBANESWAR, JANUARY 29, 2021
In a first-of-its kind study, doctors from the All India Institute of Medical Sciences (AIIMS), New Delhi have found that the synergistic effect of ayurvedic formulation BGR-34 along with allopathic drug Glibenclamide (a medication used to treat diabetes mellitus type 2) can have a significant role in improving the overall quality of life of diabetic patients and helping in lowering the risk of heart attack.
The findings hold importance given that people with diabetes are 2 to 4 times more likely than others to develop cardiovascular disease, deadly comorbidities that could put the person at the high risk of contracting Covid-19.
Giving a ray of hope, the doctors from the premier medical institute in their study found that the progression of diabetes could be delayed and risk of heart attack cut down if allopathic drug is integrated with BGR-34, a herbal formulation enriched with antioxidant properties which does not allow bad cholesterol to accumulate in the arteries of the heart.
To find efficacy of the BGR-34 with allopathic drug, doctors led by Dr. Sudhir Chandra Sarangi from the Pharmacology Department of the AIIMS New Delhi gave the ayurvedic formulation and allopathic medicine Glibenclamide separately to one group and in combination to another group.
The results were encouraging. The researchers found that the group who were given the combination of BGR-34 and Glibenclamide, had more improvement in insulin level than those given allopathic drug alone. It also showed the cholesterol lowering (cardio protective) effect. The improvement rate also accelerated from 40 days to 28 days.
“The outcome from the experimental model indicates that though both the ayurvedic and allopathic medicines are effective in controlling the biochemical parameters during management of diabetes to certain extent, the combination of the two is exclusively beneficial to patients in restoring these biomarker parameters better than the individual effect from one and nearer to the value in normal subjects,” said the report.
The study also established that BGR-34 improved lipid profile in terms of triglycerides and levels of VLDL (very low density lipoprotein which is made up of cholesterol, triglycerides, and proteins), thus showing that it can be safely taken with synthetic anti-diabetic drugs.
Anti-diabetic herbal formulation, BGR-34, developed using extracts of herbs like Giloy, Vijaysar, Daruharidra, Gudmar, Methika and Manjistha, and commercially manufactured by New Delhi-based Aimil Pharmaceuticals (I) Limited, is prepared after intensive research by CSIR’s Lucknow based labs – Central Institute of Medicinal and Aromatic Plants (CIMAP) and National Botanical Research Institute (NBRI).
Recently, a team of scientists from Tehran University had in their study concluded that herbal drugs having anti-oxidant properties can reduce the risk of Covid-19 in diabetic patients.